When used to treat chronic lymphocytic leukemia, your Arzerra dosage will depend on whether you have used other treatments before or not. In some cases, a healthcare provider will administer the intravenous (IV) infusion once a week for eight weeks, followed by a dose once every four weeks for four doses. Treatment may be completed after 12 doses are administered, which usually takes 24 weeks.
An Introduction to Dosing With ArzerraThere is only one standard dosage of Arzerra® (ofatumumab), regardless of your age or weight. As is always the case, do not adjust your dosage unless your healthcare provider specifically tells you to do so.
Recommend Arzerra DosageThe usual recommended initial dosage of Arzerra for the treatment of chronic lymphocytic leukemia (CLL) in people who have tried and failed other treatments is 300 mg. After the initial dosage, the amount will be increased to 2000 mg once a week for seven more doses, and then once every four weeks for four doses. Treatment is finished after 12 doses, which normally takes 24 weeks.
For people who have never been on other treatments for CLL, the usual recommended dosage is 300 mg for the initial dosage, followed by 100 mg one week later, and followed by 1000 mg on day 1 of 28-day cycles, for 3 to 12 cycles. For previously untreated people, a regimen of Arzerra plus chlorambucil is recommended.
Because of the risk for infusion reactions (serious reactions to the medication that may occur during or shortly after receiving the dose) from the Arzerra injection, the medication will be given slowly over several hours. The infusion may need to be interrupted if reactions occur.
In addition, your healthcare provider will give you other medicines 30 minutes to 2 hours before each Arzerra dosage to help prevent infusion reactions. This is known as premedication. Premedication with this particular treatment usually includes the following:
- Acetaminophen (Tylenol®)
- An antihistamine, such as cetirizine (Zyrtec®)
- A corticosteroid, such as prednisolone (Orapred®, Pediapred®).